Study Finds Mesothelioma Subtype Less Responsive to Treatment

A recent study confirms that the rarest and most deadly subtype of mesothelioma is less likely to show a positive response to chemotherapy treatment than other more common subtypes of mesothelioma.

Scientists from the Mayo Clinic in Minnesota and the Levine Cancer Institute in North Carolina studied 1,475 mesothelioma patients and their response to first or second-line chemotherapy. Of the group, 68% had the most common subtype – epithelioid mesothelioma. Just over 13% had biphasic tumors, and the remaining 9.3% of participants suffered from the most lethal subtype – sarcomatoid mesothelioma. The response patterns to chemotherapy treatment varied over the three types, but overall 21.9% of patients showed a measurable impact on the size of their tumors following the chemotherapy treatment.

Of the group studied, patients with the sarcomatoid subtype of mesothelioma showed a significantly lower response to treatment. Only 13.9% reported a positive impact on tumor size following chemotherapy which was eight percent lower than the overall rate. Though this information may seem discouraging to those suffering from the disease, the study focused only on those who underwent first or second-line chemotherapy. Other mesothelioma treatments options are available, including surgery and radiation, and doctors agree that a multi-modal approach usually produces the best outcomes.

Philadelphia Asbestos Lawyers at Brookman, Rosenberg, Brown & Sandler Advocate for Mesothelioma Patients

If you or a loved one has been diagnosed with mesothelioma, you may feel overwhelmed by the uncertainties the future holds. Turn to the experienced and dedicated Philadelphia asbestos lawyers at Brookman, Rosenberg, Brown & Sandler for help. We can ease your burden by fighting for the compensation you deserve to help you and your family cover medical costs, long-term care, and loss of income. We have a proven track record of success in gaining maximum awards for victims of mesothelioma and other asbestos-related diseases.

Our office is conveniently located in Center City, Philadelphia and represents clients throughout Pennsylvania and New Jersey, including Philadelphia County, Chester County and Delaware County. Call us today at 1-800-369-0899 to schedule your free consultation or submit an online contact form.

Recent Posts

Are Oil Refinery Workers at Risk for Asbestos Exposure?

Occupational hazards are associated with working at an oil refinery, from the risk of fires or explosions to being exposed…

3 weeks ago

Atlantic City School Has Asbestos: Parents, Teachers Were Not Notified

The recurring pattern of poor communication plagues both the City of Atlantic City and the Atlantic City Public Schools system…

4 weeks ago

How Can I Identify Asbestos Siding?

Asbestos shingle siding dates back to 1907, and the National Board of Fire Underwriters later endorsed it for its resistance…

2 months ago

Can I Sue for Compensation if I Have Mesothelioma?

Mesothelioma is an incurable disease that will have an immeasurable impact on both the person who was diagnosed and their…

3 months ago

Can Surgery Treat My Mesothelioma?

Depending on the kind of mesothelioma you have and whether it has progressed, treatment options may alleviate symptoms and extend…

4 months ago

Are Young Adults Getting Mesothelioma?

Mesothelioma is an aggressive form of cancer that is caused by exposure to asbestos. In most cases, mesothelioma affects people…

5 months ago
Attorney Advertising Materials. Cary Sandler is responsible for the content of this website. This website is designed for general information only. The information presented at this site should not be construed to be formal legal advice nor the formation of a lawyer/client relationship.

Disclaimer: The case results should not create an unjustified expectation that similar results can be obtained for others without regard to the specific factual and legal circumstances of your case.

© 2019 Brookman, Rosenberg, Brown & Sandler. | All Rights Reserved.
LIVE CHAT